Keap1 Antibody (OTI1B4) [PE]

Flow Cytometry: Keap1 Antibody (OTI1B4) [PE] [NBP2-71496PE] - The levels of Keap1 (NBP2-71496PE) were analyzed and quantified using geometric mean fluorescence intensity (MFI) by flow cytometry. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32765513/) licensed under a CC-BY license.

Flow Cytometry: Keap1 Antibody (OTI1B4) [PE] [NBP2-71496PE] -

Flow Cytometry: Keap1 Antibody (OTI1B4) [PE] [NBP2-71496PE] - SLD-LPS-mediated Keap1 accumulation is correlated with a pro-inflammatory monocyte phenotype. BMDMs were treated with either PBS or SLD-LPS (100 pg/mL) for 5 days. (A) Representative Co-IP result with no lysate IP (just antibody & beads) (Con.) & the whole cell lysate input (WCL) controls. Keap1 antibody was used to pull-down Nrf2 (upper blot), & Nrf2 was used to pull down Keap1 (lower blot). See Supplemental Figures S3, S4 for un-altered blots. (B–D) The levels of Ly6C (B), Keap-1 (C), & CD200R (D) were analyzed & quantified using geometric mean fluorescence intensity (MFI) by flow cytometry. (E–G) Representative western blots of IKK beta (E), p-p65 (S536) (F), & total NF-kappa B p65 (G) in monocytes with quantification on the left. (H) p-p65/total p65 ratio. All data are representative of at least 3 separate experiments (n = 3, except for IKK-beta where n = 5). Unpaired student t-test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/32765513), licensed under a CC-BY license. Not internally tested by Novus Biologicals.